| Species |
Human |
| Protein Construction |
IL-13 Variant (Gly35-Asn146)
Accession # P35225 |
|
| Purity |
> 97% as analyzed by SDS-PAGE
> 97% as analyzed by HPLC |
| Endotoxin Level |
< 1 EU/μg of protein by LAL method |
| Biological Activity |
Fully biologically active when compared to standard. The ED50 as determined by a cell proliferation assay using human TF-1 cells is less than 0.5 ng/ml, corresponding to a specific activity of > 2.0 × 106 IU/mg. |
| Expression System |
E. coli |
| Theoretical Molecular Weight |
12.3 kDa |
| Formulation |
Lyophilized from a 0.2 μm filtered solution in PBS, pH 7.2, 5% trehalose. |
| Reconstitution |
It is recommended that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute the lyophilized powder in sterile distilled water or aqueous buffer containing 0.1% BSA to a concentration of 0.1-1.0 mg/ml. |
| Storage & Stability |
Upon receiving, this product remains stable for up to 6 months at -70°C or -20°C. Upon reconstitution, the product should be stable for up to 1 week at 4°C or up to 3 months at -20°C. Avoid repeated freeze-thaw cycles. |
| Target Background |
The human IL-13 cDNA encodes a 132 amino acid protein containing a proposed 20 amino acid signal peptide. Human IL-13 shares approximately 30% amino acid sequence homology to human IL-4 and the two cytokines exhibit overlapping biological activities. Human IL-13 is produced by activated Th0, Th1-like Th2-like and CD8 T cells. Similarly to IL-4, IL-13 has multiple effects on the differentiation and functions of monocytes/macrophages. IL-13 can suppress the cytotoxic functions of monocytes/macrophages. It can also suppress the production of proinflammatory cytokines and upregulate the production of IL-1ra by monocytes/macrophages. |
| Synonyms |
Interleukin-13 Variant; IL-13 V |
For laboratory research use only. Direct human use, including taking orally and injection and clinical use are forbidden.
